Slide 1: SUJANI VASIREDDI Date:
https://vimta.com/investor- presentation/ Digitally signed by SUJANI SUJANI VASIREDDI VASIREDDI Date: 2026.05.06 16:22:06 +05'30'
Slide 2: Investor Presentation Q4 & FY26
INVESTOR PRESENTATION Q4 & FY26 1
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Table Of Contents
Table Of • Q4 & FY26 Earnings Contents • Company Overview • Industry Landscape • Our Competitive Advantage • Way Forward 3
Slide 5: Q4 & FY26 Earnings
Q4 & FY26 Earnings Section • Q4 & FY26 Highlights 01 • • Key Metrics: Q4 & FY26 Profit & Loss Statement • Financial Track Record • Shareholding Pattern 4
Slide 6: Q4 FY26 Highlights
Q4 FY26 Highlights Rs 1,120 Mn Rs 421 Mn Rs 290 Mn Margin 37.6% Total Income EBITDA PBT Rs 4.7 Rs 271 Mn Rs 211 Mn Margin 18.9% CAPEX (Cash EPS PAT Outflow) 5
Slide 7: FY26 Highlights
FY26 Highlights Rs 4,163 Mn Rs 1,489* Mn Rs 1,040* Mn Margin 35.8% Total Income EBITDA PBT Rs 17.4 Rs 650.6 Mn Rs 775 Mn Margin 18.6% Cash & Cash EPS PAT Equivalent** *Including Exceptional Item 6 **Cash and Cash equivalents includes other bank balances
Slide 8: Key Metrics: Q4 FY26
Key Metrics: Q4 FY26 Total Income EBIDTA & EBIDTA PAT & PAT Margin Basic EPS (In ₹) (In ₹ Mn) Margin (In ₹ Mn, %) (In ₹ Mn, %) EBIDTA EBIDTA Margin PAT PAT Margin 16.6% 21.5% 15.2% YoY YoY YoY 19.1% 17.5% 36.1% 18.9% 5 34.3% 37.6% 961 1,005 1120 347 344 421 183 176 211 4.1 4.0 4.7 0 Q4FY25 Q3FY26 Q4
Slide 9: Key Metrics: FY26
Key Metrics: FY26 Total Income EBIDTA & EBIDTA PAT & PAT Margin Basic EPS (In ₹) (In ₹ Mn) Margin (In ₹ Mn, %) (In ₹ Mn, %) EBIDTA EBIDTA Margin PAT PAT Margin 19.5% 18.0% 16.1% YoY YoY YoY 40% 35% 30% 36.2% 35.8% 25% 19.2% 18.6% 20% 15% 3,482 4,163 1,262 1,489 668 775 15.0 17.4 10% FY25 FY26 FY25 F
Slide 10: Profit & Loss Statement
Profit & Loss Statement Particulars (₹ Mn) Q4 FY26 Q3 FY26 QoQ(%) Q4 FY25 YoY (%) FY26 FY25 YoY (%) Revenue from Operations 1,092 986 944 4,073 3,440 Other Income 28 18 16 90 42 Total Income 1,120 1,005 11.5% 961 16.6% 4,163 3,482 19.5% Material and Testing Costs 224 193 182 807 710 Cost of lab setu
Slide 11: Financial Track Record
Financial Track Record TOTAL INCOME (₹ Mn) PROFITABILITY (₹ Mn) EBITDA & EBITDA PAT & PAT Margin Margin 19% 36% 36% 31% 33% 17% 19% 29% 15% 15% 14.6% 25% 28.6% 50.0% CAGR 18% CAGR 4% 10% CAGR 1,837 2,115 2,797 3,216 2,923 3,482 4,163 330 538 817 984 977 1,262 1,489 214 413 482 488 668 775 68 FY20 FY
Slide 12: Shareholding Pattern
Shareholding Pattern Shareholding as on 31st March 2026 Share Information as on 31st March 2026 NSE Ticker VIMTALABS BSE Ticker 524394 Market Cap (INR Cr) 1,701.01 % free-float 64.15% Others Promoters 59.12% 35.85% Free-float market cap (INR Cr) 1,091.20 Total Debt (INR Mn) 33.3 Cash & Cash Equivale
Slide 13: Company Overview
Company Overview Section • Vimta at a Glance 02 • • Our Journey Our Offerings • Geographical Presence • Management 12
Slide 14: Vimta at a Glance
Vimta at a Glance Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high-quality, cutting-edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics, sma
Slide 15: Our Journey
Our Journey Infrastructure People Investment Capabilities Revenues Pharma & Biopharma: Discovery & development 2024 600,000+ ft2 1300+ 492 M services; Food; Environment; Electronics Testing 3,223 M Analytical – Pharma, Biopharma & Food; Clinical 2015 400,000+ ft2 1000+ 580 M Research; Preclinical; C
Slide 16: Our offerings
Our offerings Drug discovery and development services Food & Agri Testing Electronics & Electricals Testing Environment Testing & Consultancy 15
Slide 17: Drug discovery and development services
1. Drug discovery and development services Offerings Pharma Analytical Clinical Research Preclinical Research Pharmaceuticals, Biologics, Medical Industry Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health Device, Agrochemical, Speciality Chemicals Accreditations & DCA, USFDA
Slide 18: Food & Agri Testing
2. Food & Agri Testing Industry Food Manufacturing & Processing, Cultivation, Export, Retail, Nutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed No. of Locations 7 (Hyderabad, Mumbai (NFL), Ahmedabad, Bengaluru, Nellore, Nashik, Noida) Accreditations & • FSSAI, ISO 17025, BIS, APEDA, EIC
Slide 19: Electricals & Electronics Testing & Certification
3. Electricals & Electronics Testing & Certification Industry Aviation, Defence, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries No. of Locations 1 (Hyderabad) Accredit
Slide 20: Environment Testing & Consultancy Services
4. Environment Testing & Consultancy Services Industry Manufacturing and Processing industries, Oil & Gas, Power, Cement, Mining, Infrastructure, etc. No. of Locations 4 (Hyderabad, Chennai, Kolkata and Noida) Accreditations & Regulatory • MoEF, ISO 17025, QCI/NABET, OSHAS 45000 Approvals • Post pro
Slide 21: Geographical Presence
Geographical Presence Food Environment Electrical and Electronics Hyderabad Hyderabad Hyderabad Ahmedabad Chennai Noida Noida Mumbai (NFL) Kolkata Nashik Bengaluru Nellore Food Electronics & Electrical Hyderabad (Headquarters) Pharma Environment 20
Slide 22: Key Management Team
Key Management Team Harriman Vungal S P Vasireddi Harita Vasireddi Sreenivas Neerukonda Siva Kambhampati Executive Director - Executive Chairman Managing Director Executive Director Chief Financial Officer Operations • Dr. S P Vasireddi is a Scientist – • Harita has close to 25 years of • Sreenivas’
Slide 23: Industry Landscape
Industry Landscape Section • Market Opportunity 03 • Factors Driving Industry Growth 22
Slide 24: Markets Opportunity (Global)
Markets Opportunity (Global) Pharmaceutical Environment Electronics Preclinical Food Testing Analytical Testing Testing Testing 14,580 14,340 36,250 9,320 7,430 3,990 25,330 (USD Mn) 9,740 Global 6,250 2,550 2025 | 2030 2024 | 2034 2025 | 2030 2025 | 2030 2023 | 2030 23
Slide 25: Markets Opportunity (Indian)
Markets Opportunity (Indian) Pharmaceutical Environment Electronics Preclinical Food Testing Analytical Testing Testing Testing 309 394 1,799 460 100 (USD Mn) Indian 185 293 211 832 50 2025 | 2030 2024 | 2030 2024 | 2033 2024 | 2030 2021 | 2028 24
Slide 26: Factors Driving Industry Growth
Factors Driving Industry Growth • Increasing demand for new drug • Surge in demand for certification innovations, growth in biologics and services of electrical & electronic vaccine products development, and increasing regulations in pharma and products, growing defence budgets biotech industry and
Slide 27: Our Competitive Advantage
Our Competitive Advantage Section • Our Position in the CRTO Landscape 04 • Our Strength 26
Slide 28: Our Position in the CRTO Landscape
Our Position in the CRTO Landscape Pharma Analytical Clinical Research Electronics & Electricals • #1 in India • Among the most reputed CROs in • One of the leading labs in • Customers – 90% of India top 20 India Southern India • 36% revenues from overseas • 75% of revenues from overseas Food Testin
Slide 29: Our Strengths
Our Strengths Infrastructure Innovations Knowledge Unparalleled lab Continuous addition Multi-disciplinary, infrastructure in the of services and knowledgeable, skilled country. Gold LEED evolving excellence and trained certified Vivarium manpower Customer Centricity Compliance Technology Long term
Slide 30: Way Forward
Way Forward Section • Our Key Growth Drivers & Strategies 05 29
Slide 31: Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies Favourable Core business Core operational Best markets strategies strategies practices Growth momentum Capacity expansions Operational excellence Good corporate governance in markets Service innovations Hiring right talent Risk management Growing d
Slide 32: Thank You
THANK YOU Vimta Labs Ltd. Registered Office Siva Kambhampati | Chief Financial Officer #142, IDA Phase 2 Cherlapally, Siva.Kambhampati@vimta.com Hyderabad Telangana, India. 500051 Ernst & Young Siddesh Chawan Advait Bhadekar NSE: VIMTALABS ISIN: INE579C01029 Siddesh.Chawan@in.ey.com Advait.Bhadekar@